Search Results - Anna Sundlöv

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

    Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry by Anna Sundlöv, Katarina Sjögreen Gleisner, Johanna Svensson, Michael Ljungberg, Tomas Olsson, Peter Bernhardt, Jan Tennvall

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab

    The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab by Daniel Castellano, Juan Manuel Sepúlveda-Sánchez, Ignacio Escobar, A. Rodrı́guez-Antolı́n, Anna Sundlöv, H. Cortés-Funes

    Published 2011
    Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with<sup>177</sup>Lu-DOTATATE

    Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with<sup>177</sup>Lu-DOTATATE by Daniel Roth, Johan Gustafsson, Carl Fredrik Warfvinge, Anna Sundlöv, Anna Åkesson, Jan Tennvall, Katarina Sjögreen Gleisner

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Bone Marrow Absorbed Doses and Correlations with Hematologic Response During <sup>177</sup>Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases

    Bone Marrow Absorbed Doses and Correlations with Hematologic Response During <sup>177</sup>Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Ske... by Linn Hagmarker, Johanna Svensson, Tobias Rydèn, Martijn van Essen, Anna Sundlöv, Katarina Sjögreen Gleisner, Peter Gjertsson, Peter Bernhardt

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients

    Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients by Anna Sundlöv, Katarina Sjögreen Gleisner, Jan Tennvall, Michael Ljungberg, Carl Fredrik Warfvinge, Kajsa Holgersson, Andreas Hallqvist, Peter Bernhardt, Johanna Svensson

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy

    Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy by Anna Sundlöv, Johan Gustafsson, Gustav Brolin, Niels Peter Mortensen, Rebecca Hermann, Peter Bernhardt, Johanna Svensson, Michael Ljungberg, Jan Tennvall, Katarina Sjögreen Gleisner

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

    Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms by Eva Tiensuu Janson, Halfdan Sørbye, Staffan Welin, Birgitte Federspiel, Henning Grønbæk, Per Hellman, Morten Ladekarl, Seppo W. Langer, Jann Mortensen, Camilla Schalin‐Jäntti, Anders Sundin, Anna Sundlöv, Espen Thiis‐Evensen, Ulrich Knigge

    Published 2014
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms

    The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms by Andreas Venizelos, Hege Elvebakken, Aurel Perren, Oleksii Nikolaienko, Wei Deng, Inger Marie Bowitz Lothe, Anne Couvelard, Geir Olav Hjortland, Anna Sundlöv, Johanna Svensson, Harrish Garresori, Christian Kersten, Eva Hofsli, Sönke Detlefsen, Merete Krogh, Halfdan Sørbye, Stian Knappskog

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Surgery of the primary tumour in 201 patients with high‐grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine‐non‐neuroendocrine neoplasms

    Surgery of the primary tumour in 201 patients with high‐grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine‐non‐neuroendocrine neoplasms by Hans‐Christian Pommergaard, Kirstine Nielsen, Halfdan Sørbye, Birgitte Federspiel, Elizaveta Mitkina Tabaksblat, Lene Weber Vestermark, Eva Tiensuu Janson, Carsten Palnæs Hansen, Morten Ladekarl, Herish Garresori, Geir Olav Hjortland, Anna Sundlöv, Renate Galleberg, Pauline Knigge, Andreas Kjær, Seppo W. Langer, Ulrich Knigge

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: